Beone Medicines

This study is testing whether the drug zanubrutinib can help control primary membranous nephropathy, a serious autoimmune kidney disease. It will compare zanubrutinib against an existing drug, tacrolimus, in about 178 adults who are already on standard supportive care. The main g…

This study is testing a new drug called sonrotoclax, both by itself and combined with another drug called zanubrutinib, for a rare blood cancer called Waldenström Macroglobulinemia. It aims to see if these treatments can shrink the cancer and control it for people whose disease h…

This study follows cancer patients who were already receiving experimental drugs in previous trials. Researchers want to understand the long-term safety of these cancer treatments, including how well patients tolerate them over extended periods. The study includes patients with v…

This is the first study in people testing a new oral drug called BG-89894 for advanced solid tumors that have a specific genetic change (MTAP deletion). The main goals are to find a safe dose, see how the body processes the drug, and look for early signs that it might help contro…

This is an early-stage study to test the safety and find the best dose of a new oral drug called BGB-11417 for adults with several types of advanced B-cell blood cancers that have come back or stopped responding to prior treatments. The study will test the drug by itself and in c…

This study is testing whether adding an experimental drug called sonrotoclax to an approved drug, zanubrutinib, works better than zanubrutinib alone for adults newly diagnosed with chronic lymphocytic leukemia (CLL). About 94 participants will be randomly assigned to receive one …

This is a very early-stage study to test the safety and initial effects of a new drug called BGB-R046. It will be given alone and in combination with an existing immunotherapy drug (tislelizumab) to about 75 people with advanced solid tumors that have spread and no longer respond…

This study tests whether a new two-drug combination (sonrotoclax plus zanubrutinib) works better than the current standard treatment (venetoclax plus obinutuzumab) for people newly diagnosed with chronic lymphocytic leukemia (CLL), a type of blood cancer. About 652 participants w…

This early-stage study aims to understand how a new combination pill containing two cancer drugs is absorbed by the body compared to taking the drugs separately. It will also test whether eating food changes how the pill works. The study involves 24 healthy adult volunteers to ga…